Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neoplasms × marizomib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 3 Recurrence 2 Lymphoma 2 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia 1 Glioma 1 Glioblastoma 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

pembrolizumab 66 Paclitaxel 56 Gemcitabine 50 Carboplatin 50 Cisplatin 39 Docetaxel 36 Bevacizumab 33 Nivolumab 28 Irinotecan 25 Pemetrexed 24 Cyclophosphamide 24 Fluorouracil 23 Capecitabine 22 Erlotinib Hydrochloride 20 venetoclax 19 Cetuximab 19 trametinib 17 Leucovorin 16 Topotecan 15 Afatinib 15 fludarabine 14 Radiotherapy 14 130-nm albumin-bound paclitaxel 14 regorafenib 13 budigalimab 13 Sorafenib 13 Oxaliplatin 13 atezolizumab 12 Doxorubicin 12 Dexamethasone 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04341311 2024-02-15

DIPG

Dana-Farber Cancer Institute

Phase 1 Terminated

Diffuse Intrinsic Pontine Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡